| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Tuesday, November 14, 2023 6:17:03 PM
Nope. Real investors looking for opportunities do that analysis. Analysts are nothing more and no, these companies do not generally themselves put out share predictions or revenue predictions pre-approval. Those are no nos and I’ve only ever heard of shady companies doing that.
The sales pitch for L is going to be extremely compelling. This is a patient category that has had only death sentences, now having a systemic treatment that by itself creates a substantial long tail of survivors, and the average is not representative because you have certain categories of patients who live much, much longer. And we know some have lived long enough to effectively be declared “cured” and nothing like that exists.
When they get to do combinations, poly-iclc and then Keytruda, we are seeing incredible expansion of patients who live longer. In one arm if the most recent paper that us submitted to Nature, we see 100% of that one arm living beyond 9 years, i believe with no recurrence but definitely still living. We see other arms with over 50% with similarly long life and across the board we see an incredible improvement in quality of life, patients going to a doctor's office and getting a shot with, compared to other kinds of oncology treatments, experiencing virtually no side-effects.
No one would expect an anonymous short to state the honest benefits of treatment they are shorting. The great thing about longs is the company has a limited pool of people and if we were promoting lies, we know we can easily be discovered because it is a small pool of names.
Short posters likely are hired, and even if they are known to their brokers, wherever they are in the world, they are a much more nefarious lot who believe they are untouchable.
The sales pitch for L is going to be extremely compelling. This is a patient category that has had only death sentences, now having a systemic treatment that by itself creates a substantial long tail of survivors, and the average is not representative because you have certain categories of patients who live much, much longer. And we know some have lived long enough to effectively be declared “cured” and nothing like that exists.
When they get to do combinations, poly-iclc and then Keytruda, we are seeing incredible expansion of patients who live longer. In one arm if the most recent paper that us submitted to Nature, we see 100% of that one arm living beyond 9 years, i believe with no recurrence but definitely still living. We see other arms with over 50% with similarly long life and across the board we see an incredible improvement in quality of life, patients going to a doctor's office and getting a shot with, compared to other kinds of oncology treatments, experiencing virtually no side-effects.
No one would expect an anonymous short to state the honest benefits of treatment they are shorting. The great thing about longs is the company has a limited pool of people and if we were promoting lies, we know we can easily be discovered because it is a small pool of names.
Short posters likely are hired, and even if they are known to their brokers, wherever they are in the world, they are a much more nefarious lot who believe they are untouchable.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
